COMP <GO>
INAB vs PASG // EV/EBITDA & P/E VALUATION
IN8bio Inc. (NASDAQ) VS. Passage Bio Inc. (NASDAQ) • 15-METRIC TALLY: INAB 0
— PASG 2
■ METRIC PARITY
LAST: $0.98 (-3.91%) • MKT CAP: $9.7M
valuation
—
LAST: $3.52 (+5.71%) • MKT CAP: $11.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INAB VS. PASG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INAB | PASG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.5 | 38.6 | -5.10 | PASG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.7M | $11.3M | -$1.7M | PASG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INAB REV | PASG REV | INAB GROSS % | PASG GROSS % | INAB FCF | PASG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$12.7M | -$31.5M |
| FY 2024 | $0 | $0 | — | — | -$24.1M | -$48.0M |
| FY 2023 | $0 | $0 | — | — | -$23.3M | -$78.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INAB // BETA —
PASG // BETA —